DNAPrint to Phase Out ANCESTRYbyDNA(TM) 2.0 in Favor of More Advanced Technology
Thursday April 29, 11:32 am ET
SARASOTA, Fla., April 29 /PRNewswire-FirstCall/ -- DNAPrint genomics (OTC Bulletin Board: DNAP - News) of Sarasota, FL (the "Company") announced today that it is discontinuing its ANCESTRYbyDNA(TM) 2.0 (ABD 2.0) testing service commencing June 1, 2004.
The move allows the Company to focus its consumer genomics service resources on its technologically superior ANCESTRYbyDNA(TM) 2.5.
Until the close out date of June 1, 2004, the Company will be offering the ANCESTRYbyDNA 2.0 test for $99. This test will no longer be available through any of the Company's distributors and for a limited time, starting May 1, 2004 can only be ordered directly from the Company at the $99 price. The test is used to help determine a person's genetic heritage such as sub Saharan African, East Asian, Native American and Indo European. Genealogy studies linked to genetic ancestry helps individuals connect to their origins. It is the only test of its kind available to the public.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company introduced ANCESTRYbyDNA(TM) in the consumer market and DNA Witness(TM) in the forensic market in 2003. DNAPrint(TM) is developing products in the pharmacogenomic market and has a disease gene discovery program. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com. ANCESTRYbyDNA(TM) 2.0 or 2.5 can be ordered by linking to www.ancestrybydna.com
All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. |
